Pfizer Inc. – Product Pipeline Review – 2014 Reference Code: GMDHC06172CDB Publication Date: SEP 2014 Pfizer Inc. – Product Pipeline Review – 2014 GMDHC06172CDB / Published SEP 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Pfizer Inc. – Product Pipeline Review Table of Contents Table of Contents ....................................................................................................................................................................... 2 List of Tables ....................................................................................................................................................................... 22 List of Figures ...................................................................................................................................................................... 22 Pfizer Inc. Snapshot ................................................................................................................................................................. 23 Pfizer Inc. Overview ............................................................................................................................................................. 23 Key Information ................................................................................................................................................................... 23 Key Facts ............................................................................................................................................................................ 23 Pfizer Inc. – Research and Development Overview.................................................................................................................... 24 Key Therapeutic Areas ......................................................................................................................................................... 24 Pfizer Inc. – Pipeline Review ..................................................................................................................................................... 28 Pipeline Products by Stage of Development.......................................................................................................................... 28 Pipeline Products – Monotherapy ......................................................................................................................................... 29 Pipeline Products – Combination Treatment Modalities ......................................................................................................... 30 Pipeline Products – Partnered Products................................................................................................................................ 31 Partnered Products/Combination Treatment Modalities ..................................................................................................... 32 Pipeline Products – Out-Licensed Products .......................................................................................................................... 34 Out-Licensed Products/Combination Treatment Modalities ............................................................................................... 35 Pfizer Inc. – Pipeline Products Glance ....................................................................................................................................... 37 Pfizer Inc. – Late Stage Pipeline Products ............................................................................................................................ 37 Pre-Registration Products/Combination Treatment Modalities ........................................................................................... 37 Filing rejected/Withdrawn Products/Combination Treatment Modalities ............................................................................. 38 Phase III Products/Combination Treatment Modalities ...................................................................................................... 39 Pfizer Inc. – Clinical Stage Pipeline Products ........................................................................................................................ 41 Phase II Products/Combination Treatment Modalities ....................................................................................................... 41 Phase I Products/Combination Treatment Modalities ........................................................................................................ 43 Pfizer Inc. – Early Stage Pipeline Products ........................................................................................................................... 45 Preclinical Products/Combination Treatment Modalities .................................................................................................... 45 Discovery Products/Combination Treatment Modalities ..................................................................................................... 47 Pfizer Inc. - Unknown Stage Pipeline Products...................................................................................................................... 48 Unknown Products/Combination Treatment Modalities ..................................................................................................... 48 Pfizer Inc. – Drug Profiles ......................................................................................................................................................... 49 (bazedoxifene acetate + conjugated estrogens) .................................................................................................................... 49 Product Description ......................................................................................................................................................... 49 Mechanism of Action ....................................................................................................................................................... 49 R&D Progress ................................................................................................................................................................. 49 bazedoxifene acetate ........................................................................................................................................................... 50 Product Description ......................................................................................................................................................... 50 Mechanism of Action ....................................................................................................................................................... 50 R&D Progress ................................................................................................................................................................. 50 bosutinib .............................................................................................................................................................................. 51 Product Description ......................................................................................................................................................... 51 Mechanism of Action ....................................................................................................................................................... 51 Pfizer Inc. – Product Pipeline Review – 2014 GMDHC06172CDB / Published SEP 2014 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Pfizer Inc. – Product Pipeline Review R&D Progress ................................................................................................................................................................. 51 palbociclib ........................................................................................................................................................................... 53 Product Description ......................................................................................................................................................... 53 Mechanism of Action ....................................................................................................................................................... 53 R&D Progress ................................................................................................................................................................. 53 PF-05212366 ....................................................................................................................................................................... 56 Product Description ......................................................................................................................................................... 56 Mechanism of Action ....................................................................................................................................................... 56 R&D Progress ................................................................................................................................................................. 56 celecoxib ............................................................................................................................................................................. 58 Product Description ........................................................................................................................................................